LCTX

Lineage Cell Therapeutics, Inc.

LCTX · CIK 876343 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$9M
20172024
Net Income−$19M
20172024
Operating CF−$23M
20172024
Free Cash Flow−$24M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Gross Profit—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$0.0B$-0.0B$-0.0B$-0.1B
EPS (Basic)$-0.09$-0.03$-0.03$-0.17$0.01$-0.03$-0.36$-0.58
EPS (Diluted)$-0.09$-0.03—————$-0.17

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B$0.2B
Current Assets$0.1B$0.0B$0.1B$0.1B$0.0B$0.1B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.2B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$0.0B$-0.0B$0.0B$0.0B$0.0B$0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.1B
← Companies